Program Profile


MSD* has SPARTA programs that are currently active in more than 20 countries worldwide, including several LMICs.

SPARTA draws on input from patients and providers across different disease areas and geographies to provide customized informational and motivational support to empower patients.

SPARTA provides support to patients receiving various therapies to improve adherence to NCD treatments. It consists of various patient touch points providing telephone support,  text/email reminders, remote monitoring, symptom management tools, and disease education to help patients understand their condition better, realize the importance of diet and exercise in managing their condition and, ultimately, improve medication adherence.

Originally developed in Australia, the SPARTA platform has been rolled out in more than 20 countries, adapting to local government priorities and patient needs.

*MSD is known as Merck & Co., Inc. in the United States & Canada

The data for this program has been reviewed by both the companies and the Access Observatory team.

Access Accelerated in Action articulates the six cross-cutting principles that underpin the initiative’s commitment to strengthening NCD programs.

Through a series of 19 case studies, the report examines how member companies have incorporated these principles into their programmatic work.

Read the full report here.